Introduction {#sec1-1}
============

Breast cancer is the leading malignancy all around the globe among women, but it is uncommon in men. Breast cancer accounts for \<1% of all cancer in male with estimated lifetime risk of getting breast cancer is about 1 in 1000 in men.\[[@ref1][@ref2]\] Incidence of male breast cancer has increased by 26% over the past 25 years.\[[@ref3]\] Literature pertaining to male breast cancer is sparse, particularly in our country.\[[@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11]\] The present study was done with an aim to analyze the clinicopathological and survival characteristics of male breast cancer patients.

Methods {#sec1-2}
=======

We analyzed clinico-pathological, management and follow up details retrospectively from 2010 to 2016. Continuous variables were presented as mean ± standard deviation and median. Kaplan--Meier survival analysis was used to find out overall survival (OS) and disease-free survival (DFS), and log-rank test was used to calculate *P* value. The analysis was done using the Statistical Package for Social Sciences 21.0 (SPSS Version 21.0).

Results {#sec1-3}
=======

Total 27 patients were identified. The majority of the patients were from Delhi (13/27). No risk factor identified except family history in two cases. Clinicopathological details are depicted in [Table 1](#T1){ref-type="table"}. Most common location was central quadrant (16/27), followed by upper outer quadrant (4/27). Most common stage at presentation was Stage II.

###### 

Clinical and pathological profile of male breast cancer patients
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All patients underwent modified radical mastectomy upfront. Infiltrating ductal carcinoma found in 85.2% cases followed by infiltrating lobular carcinoma and infiltrating mucinous carcinoma in two patients each. 77.8% were hormone receptor (HR) positive while 18.5% were triple negative.

Prolonged drain output seen in three patients while one developed wound dehiscence. Two patients developed arm edema, and both of them had received adjuvant radiotherapy.

Nineteen patients received adjuvant chemotherapy while six received adjuvant radiotherapy. Two patients received both form of adjuvant treatment. All patients with HR positivity received adjuvant tamoxifen.

Median duration of follow-up was 32.75 months (6--66 months). Three patients developed local recurrence (1 chest wall and 2 ipsilateral axillae). Two patients developed distant metastasis (lung and bone). At the past follow-up, one patient with metastasis died of the disease. Actuarial OS at 5 years was 92.30% with median DFS was 76.30%. Triple-negative breast cancer (TNBC) and HR-negative status associated with poor DFS; however, there was no significant difference in OS \[[Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\].

![Showing actuarial survival at 5 years: Overall Survival (Panel: A), Disease free survival (Panel: B), Disease free survival (DFS) in relation to nodal (Panel: C) and hormonal status (Panel: D).](SAJC-6-141-g002){#F1}

###### 

Survival outcomes of male breast cancer patients
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Discussion {#sec1-4}
==========

Breast cancer is the most common malignancy among Indian women but its uncommon in men.\[[@ref1][@ref2]\] We have summarized the data on available Indian series on male breast cancer \[[Table 3](#T3){ref-type="table"}\].\[[@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11]\] Clinical and demographic finding are in concordance with the reported Indian series. Most studies show that male breast cancer presents in an advanced stage while most of our patients were in early stage. The reason may be due to the growing cancer awareness in a metro city such as Delhi as \>60% of our patients were from Delhi.

###### 

Review of Indian series on male breast cancer. \**P* stage also shown to significant prognostic variable for overall survival ^†^median OS for stage 1, 2, 3 and 4: 36.2, 32.9, 14.2 and 5.46 months respectively
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Several Western series have reported 5 years OS 80%--90% in Stage I, 50%--80% in Stage II, 30%--50% in Stage III, and \<10% in Stage IV disease.\[[@ref12][@ref13]\] Staging, nodal status, and HR^+^ have been reported as prognostic variables for OS and DFS. On univariate analysis, OS was poor in advanced stage, N^+^ and TNBC cases, but did not reach statistical significance. DFS was adversely affected by T stage and nodal status, but the difference did not reach significance, which may be because of small sample size. HR positivity associated with significantly improved DFS. These results may be not true picture as our study has small sample size and relatively less number of patients in advanced stage disease.

Conclusion {#sec1-5}
==========

Carcinoma breast in male management principles are translated from our understanding of breast cancer in women. The prognosis is dependent on stage of the disease and HR status. Most of the analysis in our study was in concordance with the available data except the stage at presentation. In our study, the predominant stage at presentation was Stage II. This may be due to raising awareness among the population in the metro cities, which is a welcome trend.

Financial support and sponsorship {#sec2-1}
---------------------------------

Nil.

Conflicts of interest {#sec2-2}
---------------------

There are no conflicts of interest.
